Ardsley Advisory Partners’s Edwards Lifesciences EW Stock Holding History

Ardsley Advisory Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$200K	–	160
2020 Q3	$200K	Buy	+2,500	New	+$195K	0.04%	130
2017 Q3	–	Sell	-12,000	Closed	-$473K	–	140
2017 Q2	$473K	Buy	12,000 +4,500	+60%	+$164K	0.07%	97
2017 Q1	$235K	Buy	+7,500	New	+$235K	0.04%	128
2016 Q4	–	Sell	-120,000	Closed	-$4.82M	–	146
2016 Q3	$4.82M	Buy	120,000 +112,500	+1,500%	+$4.24M	0.76%	48
2016 Q2	$249K	Buy	+7,500	New	+$257K	0.04%	118
2013 Q4	–	Sell	-30,000	Closed	-$348K	–	175
2013 Q3	$348K	Buy	+30,000	New	+$351K	0.07%	94

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Ardsley Advisory Partners's EW Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Edwards Lifesciences (EW) in Q4 2020, closing a stake of 2,500 shares — an estimated $200K sold.

Ardsley Advisory Partners first reported a position in EW in Q3 2013 and held it in 6 quarters. The position peaked at $4.82M in Q3 2016. 1,160 funds tracked by Wall St. Rank hold EW as of Q4 2020.

Ardsley Advisory Partners reported no remaining Edwards Lifesciences position as of Q4 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 2,500 Edwards Lifesciences shares in Q4 2020, an estimated $200K.
Ardsley Advisory Partners first reported a position in Edwards Lifesciences in Q3 2013 and held it in 6 quarters.
Ardsley Advisory Partners's Edwards Lifesciences position peaked at $4.82M in Q3 2016.
1,160 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.